Several corporates backed a $68m series D round for microbiome drug developer Vedanta Biosciences while grooming brand owner Pangaea raised the same amount from investors including Unilever.
Funding
US-based microbiome therapy developer Vedanta Biosciences completed a $68m series D round yesterday that included a $25m investment from pharmaceutical firm Pfizer and additional cash from synthetic rubber producer JSR Corporation, healthcare services provider SymBiosis and Fosun Health Capital, a vehicle for conglomerate Fosun. Affiliates of Magnetar Capital led the round, which also featured Verition Fund Management, PureTech Health, Rock Springs Capital, Skyviews Life Science, Shumway Capital and Seventure Partners’ Health for Life Capital subsidiary. Vedanta had previously…
